Loading clinical trials...
Loading clinical trials...
The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate resp...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Abbott
NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more
NCT04402086 · Rheumatic Diseases, Adult Onset Still Disease, and more
NCT04806620 · Post-Acute COVID-19 Syndrome, ME/CFS, and more
NCT07172360 · Active Ankylosing Spondylitis
NCT07261644 · Ankylosing Spondylitis
Birmingham, Alabama
Mobile, Alabama
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions